Improving the science of abuse assessment before a drug is marketed is a unified goal for the FDA and pharmaceutical industry. It is the hope that public health will be protected through placing appropriate controls, such as accurate labeling information and marketing practices, to reduce the likelihood that a drug will be abused after FDA approval.
Explore related content and topics
Page
Ewoud-Jan van Hoogdalem, Vice President of Scientific Affairs, Clinical Pharmacology
We measure our HQ with actions, experiences, and intentions. Nowhere is that more evident that in the stories of our subject matter experts. We want…
Poster
A Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Outpatient Clinical Trials in Subjects with Schizophrenia or Schizoaffective Disorder
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in a meta-analysis to be as high as 76%. The…
Publication
Successful Adaptation to the Evolution of Complex Dose Escalation Within a Large Master Protocol Basket Design Across IO Co-Therapies
A case study describing a Phase I dose escalation and cohort expansion study of an immune checkpoint inhibitor in patients with advanced solid…